Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MELA Sciences to Participate in Upcoming 12th Annual Needham Healthcare Conference



MELA Sciences to Participate in Upcoming 12th Annual Needham Healthcare
Conference

IRVINGTON, N.Y., April 15, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercizlizing MelaFind^®, today announced that it will be participating in
the upcoming Needham Growth Conference, being held April 30 – May 1, 2013 at
the Westin Grand Central Hotel in New York.

Joseph V. Gulfo, MD, MELA Sciences President and CEO will be presenting at the
conference on Wednesday, May 1 at 12:50pm ET.

To access a live webcast of the Needham presentation, visit the investor
relations section of www.melasciences.com. A replay will be available on the
company's website for two weeks following the presentation.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind^®, and its further design and development.
MelaFind is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind^® achieves market acceptance or becomes commercially
viable. Given the uncertainties affecting companies in the medical device
industry such as the Company, any or all of these forward-looking statements
may prove to be incorrect. Therefore, you should not rely on any such factors
or forward-looking statements. The Company urges you to carefully review and
consider the disclosures found in its filings with the SEC which are available
at www.sec.gov  and www.melasciences.com.

CONTACT: For further information contact:
        
         For Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         For Media
         Erica Sperling
         Rpr Marketing Communications
         212-317-1462
         erica.sperling@rprmc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement